Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients.

Sharma G, Mirza S, Parshad R, Gupta SD, Ralhan R.

Tumour Biol. 2012 Dec;33(6):1837-43. doi: 10.1007/s13277-012-0443-y. Epub 2012 Jun 29.

PMID:
22744714
2.

Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.

Sharma G, Mirza S, Parshad R, Srivastava A, Gupta SD, Pandya P, Ralhan R.

Life Sci. 2010 Jul 17;87(3-4):83-91. doi: 10.1016/j.lfs.2010.05.001. Epub 2010 May 12.

PMID:
20470789
3.

Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer.

Spitzwieser M, Holzweber E, Pfeiler G, Hacker S, Cichna-Markl M.

Breast Cancer Res. 2015 Sep 14;17:125. doi: 10.1186/s13058-015-0637-5.

4.

Prevalence and clinicopathologic correlates of O⁶-methylguanine-DNA methyltransferase methylation status in patients with triple-negative breast cancer treated preoperatively by alkylating drugs.

Fumagalli C, Della Pasqua S, Bagnardi V, Cardillo A, Sporchia A, Colleoni M, Viale G, Barberis M, Pruneri G.

Clin Breast Cancer. 2014 Aug;14(4):285-90. doi: 10.1016/j.clbc.2014.02.010. Epub 2014 Mar 2.

PMID:
24709436
5.

Protein expression and methylation of MGMT, a DNA repair gene and their correlation with clinicopathological parameters in invasive ductal carcinoma of the breast.

Asiaf A, Ahmad ST, Malik AA, Aziz SA, Rasool Z, Masood A, Zargar MA.

Tumour Biol. 2015 Aug;36(8):6485-96. doi: 10.1007/s13277-015-3339-9. Epub 2015 Mar 29.

PMID:
25820821
6.

Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma.

Nakamichi I, Tomita Y, Zhang B, Sugiyama H, Kanakura Y, Fukuhara S, Hino M, Kanamaru A, Ogawa H, Aozasa K.

Ann Hematol. 2007 Aug;86(8):557-64. Epub 2007 May 17.

PMID:
17508213
7.

Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients.

Avraham A, Uhlmann R, Shperber A, Birnbaum M, Sandbank J, Sella A, Sukumar S, Evron E.

Int J Cancer. 2012 Oct 1;131(7):E1166-72. doi: 10.1002/ijc.27526. Epub 2012 Apr 4.

8.

Germline mutations in DNA repair genes may predict neoadjuvant therapy response in triple negative breast patients.

Spugnesi L, Gabriele M, Scarpitta R, Tancredi M, Maresca L, Gambino G, Collavoli A, Aretini P, Bertolini I, Salvadori B, Landucci E, Fontana A, Rossetti E, Roncella M, Naccarato GA, Caligo MA.

Genes Chromosomes Cancer. 2016 Dec;55(12):915-924. doi: 10.1002/gcc.22389. Epub 2016 Jul 26.

PMID:
27328445
9.

Protein expression and methylation of DNA repair genes hMLH1, hMSH2, MGMT and BRCA1 and their correlation with clinicopathological parameters and prognosis in basal-like breast cancer.

Alkam Y, Mitomi H, Nakai K, Himuro T, Saito T, Takahashi M, Arakawa A, Yao T, Saito M.

Histopathology. 2013 Nov;63(5):713-25. doi: 10.1111/his.12220. Epub 2013 Sep 5.

PMID:
24004112
10.

Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 protein expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients.

Nakai K, Mitomi H, Alkam Y, Arakawa A, Yao T, Tokuda E, Saito M, Kasumi F.

Cancer Chemother Pharmacol. 2012 Apr;69(4):923-30. doi: 10.1007/s00280-011-1777-7. Epub 2011 Nov 15.

PMID:
22083523
11.

[Correlation of BRCA1 and APC aberrant methylation with the response to anthracycline-based neoadjuvant chemotherapy in primary breast cancer].

Yuan P, Xu Y, Ouyang T, Wang TF, Fan ZQ, Fan T, Lin BY, Xie YT, Li JF.

Zhonghua Zhong Liu Za Zhi. 2009 Apr;31(4):282-6. Chinese.

PMID:
19615284
12.

Identification of promoter region methylation patterns of MGMT, CDKN2A, GSTP1, and THBS1 genes in intracranial meningioma patients.

Aydemir F, Yurtcu E, Balci TB, Sahin FI, Gulsen S, Altinors N.

Genet Test Mol Biomarkers. 2012 May;16(5):335-40. doi: 10.1089/gtmb.2011.0245. Epub 2012 Jan 30.

PMID:
22288845
13.

Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients.

Fumagalli C, Pruneri G, Possanzini P, Manzotti M, Barile M, Feroce I, Colleoni M, Bonanni B, Maisonneuve P, Radice P, Viale G, Barberis M.

Breast Cancer Res Treat. 2012 Jul;134(1):131-7. doi: 10.1007/s10549-011-1945-9. Epub 2012 Jan 8.

PMID:
22228432
14.

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.

Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, Aldape KD.

Neuro Oncol. 2010 Feb;12(2):116-21. doi: 10.1093/neuonc/nop020. Epub 2009 Dec 14. Erratum in: Neuro Oncol. 2010 Jun;12(6):617.

15.

Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients.

Sharma G, Mirza S, Yang YH, Parshad R, Hazrah P, Datta Gupta S, Ralhan R.

Cell Oncol. 2009;31(6):487-500. doi: 10.3233/CLO-2009-0507.

16.

MGMT methylation assessment in glioblastoma: MS-MLPA versus human methylation 450K beadchip array and immunohistochemistry.

Trabelsi S, Mama N, Ladib M, Karmeni N, Haddaji Mastouri M, Chourabi M, Mokni M, Tlili K, Krifa H, Yacoubi MT, Saad A, H'mida Ben Brahim D.

Clin Transl Oncol. 2016 Apr;18(4):391-7. doi: 10.1007/s12094-015-1381-0. Epub 2015 Aug 20.

PMID:
26289551
17.

Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women.

Singh LC, Chakraborty A, Mishra AK, Devi TR, Sugandhi N, Chintamani C, Bhatnagar D, Kapur S, Saxena S.

Med Oncol. 2012 Jun;29(2):539-46. doi: 10.1007/s12032-011-9952-6. Epub 2011 Apr 29.

PMID:
21528410
18.

DNA methylation and breast tumor clinicopathological features: The Western New York Exposures and Breast Cancer (WEB) study.

Callahan CL, Wang Y, Marian C, Weng DY, Eng KH, Tao MH, Ambrosone CB, Nie J, Trevisan M, Smiraglia D, Edge SB, Shields PG, Freudenheim JL.

Epigenetics. 2016 Sep;11(9):643-652. doi: 10.1080/15592294.2016.1192735. Epub 2016 May 31.

19.

BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.

Takada M, Nagai S, Haruta M, Sugino RP, Tozuka K, Takei H, Ohkubo F, Inoue K, Kurosumi M, Miyazaki M, Sato-Otsubo A, Sato Y, Ogawa S, Kaneko Y.

Genes Chromosomes Cancer. 2017 May;56(5):405-420. doi: 10.1002/gcc.22445. Epub 2017 Mar 7.

PMID:
28124401
20.

Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RARβ2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay.

Yamamoto N, Nakayama T, Kajita M, Miyake T, Iwamoto T, Kim SJ, Sakai A, Ishihara H, Tamaki Y, Noguchi S.

Breast Cancer Res Treat. 2012 Feb;132(1):165-73. doi: 10.1007/s10549-011-1575-2. Epub 2011 May 19.

PMID:
21594664

Supplemental Content

Support Center